Cristina Agullo

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Harmonizing M-protein analysis: an international, multi-center reproducibility study of mass spectrometry and evaluation of concordance to electrophoretic methods.

Harmonizing M-protein analysis: an international, multi-center reproducibility study of mass spectrometry and evaluation of concordance to electrophoretic methods.

Journal: Clinical chemistry and laboratory medicine

Published: May 27, 2026

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis.

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis.

Journal: Biomedicines

Published: October 16, 2025

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

Journal: HemaSphere

Published: August 21, 2025

Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part III: Clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry.

Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part III: Clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry.

Journal: Clinical chemistry and laboratory medicine

Published: August 13, 2025

Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance.

Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance.

Journal: Blood cancer journal

Published: April 13, 2025

Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience.

Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience.

Journal: Cancers

Published: March 22, 2025

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 01, 2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Journal: Haematologica

Published: April 23, 2024

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Journal: Blood

Published: April 16, 2024

Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells.

Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells.

Journal: British journal of haematology

Published: March 23, 2024

Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma.

Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma.

Journal: Biomedicines

Published: February 26, 2024

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Journal: Blood advances

Published: December 03, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026